论文部分内容阅读
The research interest in nanonedicine has grown rapidly over the last decade.Among various nanostructures, poly(N-(2-hydroxypropyl)methacrylamide (PHPMA)drug conjugates have demonstrated numerous advantages,1 However, although HPMA copolymer-anticancer drug conjugates have been evaluated in clinical trials since early 1990s, no product entered clinical use yet.